|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for MAP1LC3B |
 Gene summary |
| Basic gene Info. | Gene symbol | MAP1LC3B |
| Gene name | microtubule-associated protein 1 light chain 3 beta | |
| Synonyms | ATG8F|LC3B|MAP1A/1BLC3|MAP1LC3B-a | |
| Cytomap | UCSC genome browser: 16q24.2 | |
| Type of gene | protein-coding | |
| RefGenes | NM_022818.4, | |
| Description | MAP1 light chain 3-like protein 2MAP1A/MAP1B LC3 BMAP1A/MAP1B light chain 3 Bautophagy-related ubiquitin-like modifier LC3 Bmicrotubule-associated proteins 1A/1B light chain 3B | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 609604 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000140941 | ||
| HPRD : 14358 | ||
| Vega : OTTHUMG00000137654 | ||
| Protein | UniProt: Q9GZQ8 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_MAP1LC3B | |
| BioGPS: 81631 | ||
| Pathway | NCI Pathway Interaction Database: MAP1LC3B | |
| KEGG: MAP1LC3B | ||
| REACTOME: MAP1LC3B | ||
| Pathway Commons: MAP1LC3B | ||
| Context | iHOP: MAP1LC3B | |
| ligand binding site mutation search in PubMed: MAP1LC3B | ||
| UCL Cancer Institute: MAP1LC3B | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for MAP1LC3B |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | I23,D19 | R21G | SKCM | 1 | I23,D19 | R21Q | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for MAP1LC3B |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | D19 | R21G | -1.4190165 | I23 | R21G | -1.4190165 | I23 | R21Q | -1.1893782 | D19 | R21Q | -1.1893782 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for MAP1LC3B from PDB |
| Top |
| Differential gene expression and gene-gene network for MAP1LC3B |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for MAP1LC3B |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for MAP1LC3B |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of MAP1LC3B go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | III | Peptide ligand (ASN,SER,SER,GLY,SER,SER,GLU,ASP,SER,PHE,VAL,GLU,ILE,ARG,MET,ALA,GLU) | 2lue | A | D19 I23 | III | Peptide ligand (GLY,GLY,ASP,ASP,ASP,TRP,THR,HIS,LEU,SER) | 2zjd | A | I23 | III | Peptide ligand (ASP,ASP,TRP,THR,HIS,LEU,SER) | 2zjd | C | I23 | III | Peptide ligand (ASP,ALA,VAL,PHE,ASP,ILE,ILE,THR,ASP,GLU,GLU,LEU) | 5d94 | A | I23 |
| Top |
| Conservation information for LBS of MAP1LC3B |
| Multiple alignments for Q9GZQ8 in multiple species |
| LBS | AA sequence | # species | Species | D19 | EQRVEDVRLIR | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | D48 | QLPVLDKTKFL | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | F108 | KDEDGFLYMVY | 2 | Homo sapiens, Bos taurus | F108 | RDEDGFLYMVY | 2 | Mus musculus, Rattus norvegicus | F52 | LDKTKFLVPDH | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | H27 | LIREQHPTKIP | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | H57 | FLVPDHVNMSE | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | I23 | EDVRLIREQHP | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | I66 | SELIKIIRRRL | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | K30 | EQHPTKIPVII | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | K49 | LPVLDKTKFLV | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | K51 | VLDKTKFLVPD | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | L53 | DKTKFLVPDHV | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | L63 | VNMSELIKIIR | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | P32 | HPTKIPVIIER | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | P55 | TKFLVPDHVNM | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | R10 | KTFKQRRTFEQ | 2 | Homo sapiens, Bos taurus | R10 | KTFKQRRSFEQ | 2 | Mus musculus, Rattus norvegicus | R11 | TFKQRRTFEQR | 2 | Homo sapiens, Bos taurus | R11 | TFKQRRSFEQR | 2 | Mus musculus, Rattus norvegicus | R69 | IKIIRRRLQLN | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | R70 | KIIRRRLQLNA | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | T50 | PVLDKTKFLVP | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | V54 | KTKFLVPDHVN | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | V58 | LVPDHVNMSEL | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |